Ariad files counter-claim against Amgen, Wyeth
Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) announced Friday it has filed a counter-claim against Amgen Inc. (Nasdaq: AMGN) and Wyeth (NYSE: WYE) in a patent infringement suit.
In April 2006, Amgen filed a lawsuit against Cambridge, Mass.-based Ariad, which develops drugs to treat cancer. Amgen’s goal was to nullify a patent of Ariad’s in order to protect its Enbrel arthritis drug.
Later in the year, Ariad unsuccessfully sought to have the lawsuit dismissed.
Ariad Chairman and CEO Dr. Harvey Berger said his firm’s counter-claim illustrates Ariad’s “strong belief in the validity and enforceability of” its patent.
In April 2006, Amgen filed a lawsuit against Cambridge, Mass.-based Ariad, which develops drugs to treat cancer. Amgen’s goal was to nullify a patent of Ariad’s in order to protect its Enbrel arthritis drug.
Later in the year, Ariad unsuccessfully sought to have the lawsuit dismissed.
Ariad Chairman and CEO Dr. Harvey Berger said his firm’s counter-claim illustrates Ariad’s “strong belief in the validity and enforceability of” its patent.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
